Caladrius (CLBS) the former NeoStem engages in the development of proprietary cell therapy products.
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications.
CLBS is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial.
CLBS14, a CD34+ cell therapy intended as a treatment for coronary microvascular dysfunction, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is specifically formulated for intramuscular administration for the treatment of lower extremity ischemia.
A phase 2 study of CLBS12 as a treatment for critical limb ischemia recently was initiated in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations.
Founded as NeoStem in 1980, CLBS is headquartered in Basking Ridge, NJ.
November 10, 2021
RegMed Investors’ (RMi) closing bell: yet another pull-back that cut to the bone as the sector bleeds-out
November 10, 2021
RegMed Investors’ (RMi) pre-open: sector weakness should/could unfold some of the oversold
November 9, 2021
RegMed Investors’ (RMi) closing bell: sector takes yet another dive
November 9, 2021
RegMed Investors’ (RMi) pre-open: a sector retreat is not a defeat, it will just move directionally
November 8, 2021
RegMed Investors’ (RMi) closing bell: the sector faded even as small-cap stocks led on the upside and held near their highs
November 8, 2021
RegMed Investors’ (RMi) pre-open: "Skip to My (The) Lou" after a record close, a sector decline, more LPS (loss-per-share) earnings this week
November 6, 2021
RegMed Investors’ (RMi) closing bell: bag and tag ‘em, as LPS (loss-per-share) earnings define the week’s share pricing endings
November 5, 2021
RegMed Investors’ (RMi) pre-open: not so fast to the sector exit on Friday but, I'm still walking instead of running
November 4, 2021
RegMed Investors’ (RMi) closing bell: not quite wrong and almost totally correct
November 4, 2021
RegMed Investors’ (RMi) pre-open: there are sessions I am out-on-the-limb having brought a saw with me
35 companies, 1 interpreter!
Insight, foresight and recommendation
Caladrius (CLBS) -- Started 2018 at $3.70, saw a high of $4.30 dropped on February 1 to $4.12 and has been dribbling between 2/7 to 2/16 at $3.93. 3/6 – a surprise, Caladrius Biosciences (CLBS) acquired an exclusive license to a late stage CD34+ Cell Therapy Program for the treatment of Refractory Angina from Shire plc (SHP.L) (SHPG). CLBS had closed at $5.03 and was up +$1.58 slipping to $0.55 or +11.13% (was +31.41%) …
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors